George, Julie
Lim, Jing Shan
Jang, Se Jin
Cun, Yupeng
Ozretić, Luka
Kong, Gu
Leenders, Frauke
Lu, Xin
Fernández-Cuesta, Lynnette
Bosco, Graziella
Müller, Christian
Dahmen, Ilona
Jahchan, Nadine S.
Park, Kwon-Sik
Yang, Dian
Karnezis, Anthony N.
Vaka, Dedeepya
Torres, Angela
Wang, Maia Segura
Korbel, Jan O.
Menon, Roopika
Chun, Sung-Min
Kim, Deokhoon
Wilkerson, Matt
Hayes, Neil
Engelmann, David
Pützer, Brigitte
Bos, Marc
Michels, Sebastian
Vlasic, Ignacija
Seidel, Danila
Pinther, Berit
Schaub, Philipp
Becker, Christian
Altmüller, Janine
Yokota, Jun
Kohno, Takashi
Iwakawa, Reika
Tsuta, Koji
Noguchi, Masayuki
Muley, Thomas
Hoffmann, Hans
Schnabel, Philipp A.
Petersen, Iver
Chen, Yuan
Soltermann, Alex
Tischler, Verena
Choi, Chang-min
Kim, Yong-Hee
Massion, Pierre P.
Zou, Yong
Jovanovic, Dragana
Kontic, Milica
Wright, Gavin M.
Russell, Prudence A.
Solomon, Benjamin
Koch, Ina
Lindner, Michael
Muscarella, Lucia A.
la Torre, Annamaria
Field, John K.
Jakopovic, Marko
Knezevic, Jelena
Castaños-Vélez, Esmeralda
Roz, Luca
Pastorino, Ugo
Brustugun, Odd-Terje
Lund-Iversen, Marius
Thunnissen, Erik
Köhler, Jens
Schuler, Martin
Botling, Johan
Sandelin, Martin
Sanchez-Cespedes, Montserrat
Salvesen, Helga B.
Achter, Viktor
Lang, Ulrich
Bogus, Magdalena
Schneider, Peter M.
Zander, Thomas
Ansén, Sascha
Hallek, Michael
Wolf, Jürgen
Vingron, Martin
Yatabe, Yasushi
Travis, William D.
Nürnberg, Peter
Reinhardt, Christian
Perner, Sven
Heukamp, Lukas
Büttner, Reinhard
Haas, Stefan A.
Brambilla, Elisabeth
Peifer, Martin
Sage, Julien
Thomas, Roman K.
Article History
Received: 15 January 2015
Accepted: 15 June 2015
First Online: 13 July 2015
Competing interests
: Competing financial interests. R.K.T. is a founder and shareholder of NEO New Oncology AG, received commercial research grants from AstraZeneca, EOS and Merck KgaA and honoraria from AstraZeneca, Bayer, NEO New Oncology AG, Boehringer Ingelheim, Clovis Oncology, Daiichi-Sankyo, Eli Lilly, Johnson & Johnson, Merck KgaA, MSD, Puma, Roche and Sanofi. P.N. is a founder, CEO and shareholder of ATLAS Biolabs. ATLAS Biolabs is a service provider for genomic analyses. M.P. is a founder and shareholder of NEO New Oncology AG and receives consultation fees from NEO New Oncology AG. J.G. has been consulting for NEO New Oncology AG and G1 Therapeutics.